Last reviewed · How we verify
Stem Cell Mobilization Therapy
Stem Cell Mobilization Therapy involves the use of certain medications to stimulate the release of stem cells from the bone marrow into the bloodstream.
Stem Cell Mobilization Therapy involves the use of certain medications to stimulate the release of stem cells from the bone marrow into the bloodstream. Used for Autologous stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.
At a glance
| Generic name | Stem Cell Mobilization Therapy |
|---|---|
| Also known as | Chemomobilization, Hematopoietic Stem Cell Mobilization, Mobilization Therapy, Stem-cell mobilization |
| Sponsor | City of Hope Medical Center |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This process is typically achieved through the administration of granulocyte-colony stimulating factor (G-CSF) or other mobilizing agents, which work by binding to specific receptors on the surface of stem cells and triggering their release into the circulation. The mobilized stem cells can then be collected from the blood and used for transplantation or other therapeutic purposes.
Approved indications
- Autologous stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma
Common side effects
- Bone pain
- Fatigue
- Nausea
- Headache
- Infection
Key clinical trials
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency (PHASE2)
- Apheresis of Patients With Immunodeficiency
- Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL (PHASE2)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models (PHASE2)
- Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis (PHASE2)
- Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stem Cell Mobilization Therapy CI brief — competitive landscape report
- Stem Cell Mobilization Therapy updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI